]>
IRCT20141209020250N4 IRCT 2018-06-30 Tehran University of Medical Sciences Diphencyprone and anthralin in alopecia areata Evaluation of the efficacy and side effects of topical diphencyprone with or without topical anthralin in patients with moderate to severe alopecia areata referring to Razi Hospital Diphencyprone Clinic, 2018- 2019. 2018-07-07 anticipated 40 Complete https://irct.ir/trial/30768 interventional Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Block randomization. 3 alopecia areata. Intervention 1: Intervention group 1: 20 patients with moderate to severe alopecia areata who are receiving just topical diphencyprone. Intervention 2: Intervention group 2: 20 patients with moderate to severe alopecia areata who are receiving both topical diphencyprone and topical anthralin. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is there is no further information
public Doctor Romina Daneshmand
Razi Dermatology Hospital, Razi blind Alley, Vahdate-Islami Square, Vahdate-Islami Street, Tehran
Tehran Iran (Islamic Republic of) 1199663911 +98 21 5560 9951 r-daneshmand@razi.tums.ac.ir Tehran University of Medical Sciences scientific Doctor Romina Daneshmand
Razi Dermatology Hospital, Razi blind Alley, Vahdate-Islami Square, Vahdate-Islami Street, Tehran
Tehran Iran (Islamic Republic of) 1199663911 +98 21 5560 9951 r-daneshmand@razi.tums.ac.ir Tehran University of Medical Sciences Iran (Islamic Republic of) moderate to severe alopecia areata 18 years 65 years Both pregnancy or lactation receiving systemic immunosuppressive therapy during recent 3 months severe systemic disease (eg. hepatic or renal failure ) immunosuppression past history of severe reaction or intolerance to diphencyprone or anthralin inability to follow regular visits or cooperation with investigators participation in another clinical trial in recent 4 weeks recent active sever progressive hair loss requiring systemic immunosuppressive therapy L63 Alopecia areata Treatment - Drugs Treatment - Drugs Intervention group 1: 20 patients with moderate to severe alopecia areata who are receiving just topical diphencyprone Intervention group 2: 20 patients with moderate to severe alopecia areata who are receiving both topical diphencyprone and topical anthralin Terminal hair regrowth rate with topical diphencyprone in comparison to the combination of topical diphencyprone with topical anthralin in patients with moderate to severe alopecia areata, based of SALT score. Timepoint: before intervention and 3 and 6 months after intervention. Method of measurement: Severity of Alopecia Tool Score. Rate of change in Severity of Alopecia Tool score than the base value, after intervention and at the end of course of treatment. Timepoint: 3 and 6 months after treatment. Method of measurement: Severity of Alopecia Tool score. Comparison of response time to treatment with topical diphencyprone exclusively or combination of topical diphencyprone and anthralin. Timepoint: 3 and 6 months after intervention. Method of measurement: time duration (month). Evaluation of patients' satisfaction with topical diphencyprone with and without topical anthralin at the end of the survey, using Dermatology Life Quality Index questionnaire. Timepoint: 6 months after treatment. Method of measurement: Dermatology Life Quality Index questionnaire. Investigating side effects of treatment (eg. dermatitis , lymphadenopathy , folliculitis , urticaria and etc.). Timepoint: 3 and 6 months after treatment. Method of measurement: patient examination and history. Tehran University of Medical Sciences Approved 2018-01-31 ethics committee of Tehran University of Medical Sciences fourth floor, No 23, before Poursina Street, 16 Azar Street, Keshavarz Boulevard Tehran Tehran Iran (Islamic Republic of)